| 张玉琪1，林思祥2▲，李艳如1，唐思杰1.曲氟尿苷替匹嘧啶在转移性结直肠癌中的应用进展[J].中国医药科学,2025,(5):33-36 基金项目:山东省烟台市科技创新发展计划（2020MSGY084） |
| 曲氟尿苷替匹嘧啶在转移性结直肠癌中的应用进展 |
| Application progress of Trifluridine/Tipiracil in metastatic colorectal cancer |
| |
| DOI： |
| 中文关键词: 曲氟尿苷替匹嘧啶；化疗；结直肠癌；氟尿嘧啶类 |
| 英文关键词:Trifluridine/Tipiracil; Chemotherapy; Colorectal cancer; Fluorouracil |
| 作者 | 单位 | | 张玉琪1，林思祥2▲，李艳如1，唐思杰1 | 1.滨州医学院第二临床医学院，山东烟台 264100；2.滨州医学院烟台附属医院肿瘤中心，山东烟台 264100 |
|
| 摘要点击次数: 26 |
| 全文下载次数: 28 |
| 中文摘要: |
| [摘要] 结直肠癌（CRC）是全球常见的恶性肿瘤，早期症状不明显、诊断困难，而转移性结直肠癌（mCRC）患者预后较差。新型化疗药物曲氟尿苷替匹嘧啶（TAS-102）是一种氟尿嘧啶类药物，具有抑制肿瘤生长和血管生成的作用，能显著延长mCRC患者的中位总生存期（mOS）和中位无进展生存期（mFPS）。TAS-102的不良反应可控，已经被多个权威指南推荐为晚期三线CRC的标准化疗药物。此外，TAS-102联合多种药物尤其是靶向药物贝伐珠单抗治疗使mCRC患者有较好获益，成为治疗mCRC的新选择。本文阐述了TAS-102的作用机制及其在mCRC的临床应用，并对TAS-102新的联合治疗方案进行展望。 |
| 英文摘要: |
| [Abstract] Colorectal cancer (CRC) is a common malignant tumor in the world, and its early symptoms are not obvious, and its diagnosis is difficult. However, patients with metastatic colorectal cancer (mCRC) have a poor prognosis. Trifluridine/Tipiracil (TAS-102), a new chemotherapy drug, is a fluorouracil drug, which can inhibit tumor growth and angiogenesis, and can significantly prolong the median overall survival (mOS) and median progression free survival (mFPS) of mCRC patients. The adverse reactions of TAS-102 can be controlled, and it has been recommended by many authoritative guidelines as the standard chemotherapy drug for advanced third-line colorectal cancer. In addition, TAS-102 combined with multiple drugs, especially the targeted drug bevacizumab, has benefited mCRC patients and become a new choice for the treatment of mCRC. The function mechanism of TAS-102 and its clinical application in mCRC is expounded, and the new combined treatment scheme of TAS-102 is looked forward in this paper. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
.jpg)